Duration of prophylaxis with trimethoprim-sulfamethoxazole in patients undergoing solid organ transplantation

Infection

Volumn 40, Issue 4, 2012, Pages 473-475

  Malhotra, P ^a   Rai, S D ^a   Hirschwerk, D ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; COTRIMOXAZOLE; FOLINIC ACID; LEVOFLOXACIN; METHYLPREDNISOLONE SODIUM SUCCINATE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; PYRIMETHAMINE; SULFADIAZINE; TACROLIMUS; THYMOCYTE ANTIBODY; VANCOMYCIN;

ACUTE GRAFT REJECTION; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ARTIFICIAL VENTILATION; BRAIN BIOPSY; BRAIN EDEMA; BRONCHOSCOPY; CADAVER KIDNEY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DEATH; DIZZINESS; DYSPNEA; FEMALE; HEADACHE; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETHARGY; LIVING DONOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PNEUMOCYSTIS PNEUMONIA; RESPIRATORY FAILURE; RESPIRATORY TRACT INTUBATION; SLURRED SPEECH; TOXOPLASMOSIS; TREATMENT DURATION;

ADULT; ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; TIME FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84866736066     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0277-y     Document Type: Article

References (19)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601-14.
2. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis. 2001;33:1397-405.
3. Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant. 2009;9:S227-33.
4. Orr KE, Gould FK, Short G, et al. Outcome of Toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years. J Infect. 1994;29:249-53.
5. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation. 2009;88:135-41.
6. Di Cocco P, Orlando G, Bonanni L, et al. A systematic review of two different trimetoprim-sulfamethoxazole regimens used to prevent Pneumocystis jirovecii and no prophylaxis at all in transplant recipients: appraising the evidence. Transplant Proc. 2009;41:1201-3.
7. Rubin RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, editors. Clinical approach to infection in the compromised host. 3rd ed. New York: Plenum Publishing; 1994. p. 629-705.
8. Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim- sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med. 1990;89:255-74.
9. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation. 2009;88:380-5.
10. Arend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis. 1996;22:920-5.
11. De Castro N, Xu F, Porcher R, Pavie J, Molina JM, Peraldi MN. Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case-control study. Clin Microbiol Infect. 2010;16:1375-7.
12. Derouin F, Pelloux H; ESCMID Study Group on Clinical Para-sitology. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect. 2008;14:1089-101.
13. Martina MN, Cervera C, Esforzado N, et al. Toxoplasma gondii primary infection in renal transplant recipients. Two case reports and literature review. Transpl Int. 2011;24:e6-12.
14. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387-94.
15. Schwartz JJ, Ishitani MB, Weckwerth J, Morgenstern B, Milliner D, Stegall MD. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. Transplantation. 2007;84:715-21.
16. Schooley RT, Hirsch MS, Colvin RB, et al. Association of her-pesvirus infections with T-lymphocyte-subset alterations, glomeru-lopathy, and opportunistic infections after renal transplantation. N Engl J Med. 1983;308:307-13.
17. Cheeseman SH, Henle W, Rubin RH, et al. Epstein-Barr virus infection in renal transplant recipients. Effects of antithymocyte globulin and interferon. Ann Intern Med. 1980;93:39-42.
18. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48:772-86.
19. Louis S, Audrain M, Cantarovich D, et al. Long-term cell monitoring of kidney recipients after an antilymphocyte globulin induction with and without steroids. Transplantation. 2007;83:712-21.